BioMarin Pharmaceutical Inc.
BMRN
$66.16
$1.091.68%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 29.17% | -12.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 29.17% | -12.39% | |||
| Cost of Revenue | 6.49% | 7.13% | |||
| Gross Profit | 50.78% | -25.35% | |||
| SG&A Expenses | 23.50% | -22.88% | |||
| Depreciation & Amortization | 1,539.35% | -7.49% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.20% | -7.33% | |||
| Operating Income | 51.82% | -29.85% | |||
| Income Before Tax | -56.53% | 620.03% | |||
| Income Tax Expenses | -53.41% | 83.71% | |||
| Earnings from Continuing Operations | -57.58% | 326.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -57.58% | 326.58% | |||
| EBIT | 51.82% | -29.85% | |||
| EBITDA | 98.93% | -26.38% | |||
| EPS Basic | -57.79% | 326.25% | |||
| Normalized Basic EPS | 6.45% | -30.27% | |||
| EPS Diluted | -57.65% | 324.14% | |||
| Normalized Diluted EPS | 8.72% | -32.09% | |||
| Average Basic Shares Outstanding | 0.48% | 0.14% | |||
| Average Diluted Shares Outstanding | -1.62% | 2.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||